The following are the pivot points for the SPDR S&P 500 ETF Trust (SPY). Pivot High: $302.90, Pivot Low: $300.85. These were calculated using the DeMark method. It is generally believed to be bullish when price breaks out above the pivot high or bearish when price breaks down below the pivot low.

Pivot levels on SPY for September 13, 2019

US retail sales rose more than expected in August. U.S. retail sales rose moderately in August, driven by a jump in auto buying and healthy online sales. Source: https://www.cnbc.com/2019/09/13/us-retail-sales-august-2019.html

Goldman cuts Apple on TV+ trial

Sep. 13, 2019 7:45 AM ET|About: Apple Inc. (AAPL)|By: Brandy Betz, SA News Editor Goldman Sachs cuts its Apple (NASDAQ:AAPL) target from $187 to $165 and maintains a Neutral rating. Analyst Rod Hall says the plan to offer a trial period for Apple TV+ is “likely to have a material negative impact” on ASPs and EPS. Apple will offer one free year of TV+ with the purchase of certain types of hardware. Hall expects Apple to account for the trial as a $60 discount to the hardware/services bundle. Apple shares are down 0.5% pre-market to $221.98.

Notable open interest changes for September 13th TheFlyontheWall.com – Live News Feed Posted 13-Sep-2019 at 08:55 am EST Thursday’s total option volume of 21.1 million contracts resulted in net open interest growth of 2.15 million calls and 2.99 million puts. Square (SQ), Bank of America (BAC), AT&T (T) and Apple (AAPL) saw the greatest growth. Top five new positions opened include 25k General Electric (GE) 9/13 weekly 9 puts, 21k Microsoft (MSFT) Sep-19 142 calls, 20k Tesla (TSLA) Oct-19 50 puts, 19k Apple (AAPL) Dec-19 190 puts and 16k Bank of America (BAC) 9/13 weekly 29.5 puts.

Cellectar Biosciences initiated with a Buy at Roth Capital TheFlyontheWall.com – Live News Feed Posted 13-Sep-2019 at 08:41 am EST Roth Capital analyst Jerry Isaacson initiated Cellectar Biosciences with a Buy rating and $11 price target, saying he expects numerous efficacy readouts before the end of 2019, in R/R multiple myeloma and R/R diffuse large B-cell lymphoma. Cellectar has successfully brought CLR 131 through clinical trials targeting hematological malignancies and has a clear pathway to approval for the treatment of late-stage multiple myeloma, Isaacson tells investors in a research note.

Microsoft, Disney make cloud deal Sep. 13, 2019 8:01 AM ET|About: Microsoft Corporation (MSFT)|By: Brandy Betz, SA News Editor Microsoft (NASDAQ:MSFT) and The Walt Disney Studios (NYSE:DIS) will join DIS’s StudioLAB tech hub with the Azure platform to deliver cloud-based solutions for production and postproduction processes. The five-year deal expands on the several existing media workflows the companies have built on the back of MSFT’s strategic cloud alliance with Avid.

Stock Market News